AFT Pharmaceuticals Limited Stock

Equities

AFT

NZAFTE0001S4

Pharmaceuticals

End-of-day quote New Zealand S.E. 06:00:00 2024-06-05 pm EDT 5-day change 1st Jan Change
3.2 NZD +3.23% Intraday chart for AFT Pharmaceuticals Limited +5.96% -8.57%
Sales 2025 * 224M 139M Sales 2026 * 259M 160M Capitalization 336M 208M
Net income 2025 * 16M 9.92M Net income 2026 * 24M 14.87M EV / Sales 2025 * 1.58 x
Net Debt 2025 * 17.64M 10.93M Net Debt 2026 * 12M 7.44M EV / Sales 2026 * 1.34 x
P/E ratio 2025 *
20 x
P/E ratio 2026 *
13.6 x
Employees 100
Yield 2025 *
0.59%
Yield 2026 *
1.02%
Free-Float 25.53%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on AFT Pharmaceuticals Limited

1 day+3.23%
1 week+5.96%
Current month+3.23%
1 month+7.74%
6 months-3.61%
Current year-8.57%
More quotes
1 week
3.10
Extreme 3.1
3.20
1 month
2.60
Extreme 2.6
3.20
Current year
2.60
Extreme 2.6
3.85
1 year
2.60
Extreme 2.6
3.90
3 years
2.60
Extreme 2.6
5.00
5 years
2.60
Extreme 2.6
5.65
10 years
1.70
Extreme 1.7
5.65
More quotes
Managers TitleAgeSince
Founder - 97-09-03
Founder - 97-09-03
Director of Finance/CFO - 97-09-03
Members of the board TitleAgeSince
Director/Board Member 67 20-12-22
Chairman - 15-06-21
Founder - 97-09-03
More insiders
Date Price Change Volume
24-06-06 3.2 +3.23% 8,465
24-06-05 3.1 -1.27% 115,293
24-06-04 3.14 +1.29% 68,020
24-05-31 3.1 +2.65% 60,215
24-05-30 3.02 +1.34% 13,708

End-of-day quote New Zealand S.E., June 05, 2024

More quotes
AFT Pharmaceuticals Limited is a New Zealand-based multinational pharmaceutical company. The Company develops, markets and distributes a portfolio of pharmaceutical products across a range of therapeutic categories, which are distributed across three pharmaceutical distribution channels: over-the-counter (OTC), prescription and hospital. Its product portfolio comprises both proprietary and in-licensed products, and includes patented, branded and generic drugs. The Company develops and in-licenses products for sale by its own dedicated sales teams in Australia and New Zealand and in certain Southeast Asian markets, and out-licenses its products to local licensees and distributors in the rest of the world. A-Scabies, Allersoothe, Allersoothe Elixir, BecloClear, Bites, Calci-Tab, Candacort, Candacort Minipak, Candaderm, Coco-Scalp, Combolieve, Cromo-Fresh, Dry skin, Eczema, Emulsifying Ointment BP, Fenpaed, Fenpaed Double Strength, Ferro-Sachets, HYLO-FORTE and others.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
3.2 NZD
Average target price
3.75 NZD
Spread / Average Target
+17.19%
Consensus

Quarterly revenue - Rate of surprise